Structural variation (SV) is a significant component of the genetic etiology of both neurodevelopmental and psychiatric disorders; however, routine guidelines for clinical genetic screening have been established only in the former category. Genome-wide chromosomal microarray (CMA) can detect genomic imbalances such as copy-number variants (CNVs), but balanced chromosomal abnormalities (BCAs) still require karyotyping for clinical detection. Moreover, submicroscopic BCAs and subarray threshold CNVs are intractable, or cryptic, to both CMA and karyotyping. Here, we performed whole-genome sequencing using large-insert jumping libraries to delineate both cytogenetically visible and cryptic SVs in a single test among 30 clinically referred youth representing a range of severe neuropsychiatric conditions. We detected 96 SVs per person on average that passed filtering criteria above our highest-confidence resolution (6,305 bp) and an additional 111 SVs per genome below this resolution. These SVs rearranged 3.8 Mb of genomic sequence and resulted in 42 putative loss-of-function (LoF) or gain-of-function mutations per person. We estimate that 80% of the LoF variants were cryptic to clinical CMA. We found myriad complex and cryptic rearrangements, including a ''paired'' duplication (360 kb, 169 kb) that flanks a 5.25 Mb inversion that appears in 7 additional cases from clinical CNV data among 47,562 individuals. Following convergent genomic profiling of these independent clinical CNV data, we interpreted three SVs to be of potential clinical significance. These data indicate that sequence-based delineation of the full SV mutational spectrum warrants exploration in youth referred for neuropsychiatric evaluation and clinical diagnostic SV screening more broadly.
Structural variation (SV) is a major component of the genetic etiology of neurodevelopmental disorders. In recent years, enrichment of large, de novo copy-number variants (CNVs) and balanced chromosomal abnormalities (BCAs) has been reported and replicated in youth with autism spectrum disorder (ASD [MIM 209850]), developmental delay (DD), and intellectual disability (ID). [1] [2] [3] [4] [5] At present, genetic testing is frequently included in diagnostic evaluation of such youth, with chromosomal microarray (CMA) serving as the recommended first-tier genetic screen since 2010 based on a consensus statement in this journal. [6] [7] [8] For ASD, the use of CMA reflects the recognition that, in addition to the subset of cases with clinical features that can indicate a known genetic syndrome (e.g., Fragile X [MIM 300624]), nonsyndromic cases may benefit from genome-wide CNV evaluation. 9 Nonetheless, despite recommendations that extend across the full autism spectrum, genetic testing is not pursued for all individuals. 10 A significantly increased burden of large CNVs has also been observed in psychiatric disorders, including attention deficit hyperactivity disorder (ADHD [MIM 143465]), Tourette syndrome (MIM 137580), schizophrenia (MIM 181500), and early-onset psychosis and bipolar disorder (MIM 125480). [11] [12] [13] [14] [15] Notably, psychiatric and neurodevelopmental conditions often co-occur, 16 and findings for both rare SVs and common polymorphic risk variants suggest an overlapping etiology. 17, 18 There is no current consensus on CMA or even general genetic testing for psychiatric disorders, although its potential benefit in this population has been discussed. 19, 20 Array-based technologies such as CMA can capture relative dosage imbalances that are a consequence of aneuploidy, CNV, and unbalanced translocation. In developmental disorders, the implementation of CMA as a first-tier genome-wide screen has significantly improved diagnostic yield over conventional karyotyping or genebased mutation screening. One study of 6,539 consecutive referrals to Signature Genomics identified at least one clinically significant CNV in 17.6%-22.5% of cases, depending on the resolution of the array test performed (wholegenome BAC versus oligonucleotide). 21 In referrals for whom no causal genetic lesion is detected, however, additional SV testing is rarely pursued for mutations that are cryptic to CMA (defined herein as below the resolution of detection for a given technology), and the impact of cryptic rearrangements is therefore unknown in this population. With respect to BCAs, karyotyping remains the only conventional diagnostic method capable of surveying their presence, as illustrated in a recent prenatal diagnostic comparison of CMA and karyotyping. 22 Karyotyping transformed human genetics more than half a century ago by opening access to gross chromosomal changes through microscopic visualization of alterations to chromosome banding patterns. The method is limited to a resolution of~5-10 Mb, depending on banding patterns within the breakpoint regions, and has yet to be supplanted in diagnostic practice by higher-resolution methods for BCA detection. Moreover, cryptic BCAs are intractable to all conventional clinical genetic screening. These BCAs are not measurable at karyotype resolution or by CMA, and have not been delineated by wholeexome sequencing (WES) or low-depth whole-genome sequencing from the 1000 Genomes Project to date. 23, 24 The mutational spectrum of cryptic SVs (submicroscopic BCAs and small CNVs) therefore represents a largely uncharacterized source of potential loss-of-function (LoF) mutations in biomedical research and a blind spot in genetic diagnostics. In a series of previous studies, we have shown that whole-genome sequencing (WGS) using large inserts of several kilobases (referred to herein as jumping libraries) can delineate cytogenetically visible BCAs in both a research capacity and prenatal diagnostic practice. 5, [25] [26] [27] [28] These methods provide a single technology capable of detecting both CMA-resolution CNVs and karyotype-resolution BCAs, as well as cryptic SVs. This approach thus allows whole-genome detection of the full SV mutational spectrum at a time and cost comparable to CMA and karyotype. 26 In the current study, we used this jumping library sequencing approach to evaluate the presence and potential impact of both cytogenetically visible and cryptic chromosomal aberrations in a clinically referred sample of children and adolescents. Specifically, we sequenced youth with a range of severe neuropsychiatric disorders (NPDs; i.e., neurodevelopmental and psychiatric conditions) whom we hypothesize are enriched for LoF variation. Subjects were obtained through the Longitudinal Study of Genetic Influences on Cognition (LOGIC), which collects deep cognitive and psychiatric phenotyping and DNA on youth referred for neuropsychiatric evaluation. The study also collects abbreviated phenotypes and DNA on first-degree relatives where possible. Our goal for the current proof-of-concept project was the sequencing of genomes from 30 youth referred for clinical neuropsychiatric evaluation. We selected 29 probands (ages 4-19) as well as an affected sibling, an affected father, and a healthy mother from a four-member multiplex family (32 total subjects). Specifically, we selected the 29 consecutive cases at the time of analysis who had provided DNA via whole blood (as opposed to saliva) and who manifested particular diagnoses in order of our priorities. First, we prioritized individuals with severe early-onset psychiatric presentations reflecting the psychosis or mood disorder spectrum, regardless of their comorbidities (n ¼ 18; 62%). Second, we included youth with other neuropsychiatric disorders (i.e., autism spectrum and ADHD) and some evidence of severe presentation (i.e., comorbidity, prior psychiatric hospitalization). As shown in Table S1 available online, a total of 25 youths met full diagnostic criteria for one or more psychiatric conditions, and 7 of these met criteria for a comorbid neurodevelopmental disorder. Thus, more than half of the sample (55%) had an exclusively psychiatric disorder (see Table S1 for complete details). We note that only one sample had previously undergone CMA analysis with no significant variants detected, and no samples had been previously referred for targeted gene panel testing. All subjects provided informed consent, and this study was approved by the Institutional Review Board of Partners HealthCare.
Large-insert jumping libraries were generated using our previously published protocols, which are provided in complete detail in Hanscom and Talkowski. 27 The method generates genomic libraries in which short end reads (25 base pairs in this study) are separated by long inserts (targeted to 2.5 kb in this study), yielding very high coverage of mapped inserts spanning the genome for minimal sequencing cost. Following library preparation, sequencing was performed on all samples on an Illumina HiSeq 2000, generating a median insert size of 2.6 kb and median insert coverage of 623 per library. 27 Analysis of large-insert jumping libraries leverages spatial relationships of mated reads to trace distinctive breakpoint signatures rather than relying upon coverage from the actual nucleotides sequenced. 25 Expanding upon our previous methods to delineate karyotypically visible BCAs, 25, 28 for this study we developed a SV classifier for WGS using jumping libraries with a targeted emphasis on reducing type I (false-positive) errors that can present a major barrier to interpretation (see Figure S1 for details). In brief, we clustered anomalously mapping read pairs across all samples using BamStat and ReadPairCluster. 25 We next computed a set of metrics for each cluster based on its constituent reads and properties of the genomic region spanned by the cluster (see Figure S1 ). Each cluster was classified based on thresholds calculated from a training set of PCR and Sanger sequencing validated SVs. We executed this process within a joint calling framework to mitigate false positive variant classifications that are a consequence of reference misassembly or systematic short read alignment errors in regions with alignment biases (e.g., highly repetitive regions such as segmental duplications). Across the genomes of our 29 probands, we identified 98 deletion, 43 tandem duplication, 99 inversion, and 112 interchromosomal insertion clusters that occurred in 90% or more of probands, most of which appear to be systematic mapping errors in complex genomic regions. After excluding all reference variation and alignment artifacts, we tested the precision of our classification algorithm by investigating the inheritance of SV calls among our four-member family. We performed the initial analyses at a resolution approximately equal to the maximum insert size of all samples that the BWA aligner will designate as reads having a proper alignment (R6,305 bp in this study). Subthreshold CNV detection is therefore unreliable as deletions are indistinguishable from proper pairs below this high-confidence resolution. 29 In total, we identified 190 high-confidence SVs between both children, 188 (98.9%) of which exhibited normal Mendelian inheritance upon inspection of corresponding SV clusters in parents. We observed two events in the proband and affected sibling (a 6.5 kb interchromosomal insertion of chr9 into chr22 and a 90 kb deletion at 14q11.2) that were not in either parent, but detected in at least one other unrelated sample in our larger cohort. This suggests that these polymorphic variants were not captured or filtered in the parent (false negatives). We next considered balanced SVs smaller than our high-confidence resolution of 6.3 kb. We identified an additional 243 balanced SVs in the affected siblings. Of these 243 subthreshold SVs, 95.5% followed normal Mendelian inheritance, suggesting that our methods retain a high level of precision below 6.3 kb resolution. The potential for type II errors (false negatives) is the major limitation of exploring SV below this size resolution, as SVs localized entirely within a fragment insert cannot be detected by our methods, and small BCAs can be missed based on stochastic fluctuations in coverage. Therefore, while we do detect many small balanced SV events, this is likely to be a significant underestimate of the total SVs present in a given genome below our highest-confidence resolution. Sequencing in all probands identified a total of 650 variants larger than the 6.3 kb high-confidence resolution threshold (362 private, 288 polymorphic), resulting in a median of 96 SVs per proband. We found an additional 354 variants (88 private, 266 polymorphic) below our high-confidence resolution, resulting in an additional 111 SVs per proband. In sum, these events correspond to 112 deletions, 13 tandem duplications, 31 balanced (Table 1 ). The majority of the CCRs were cryptic to karyotyping and CMA, suggesting that CCRs may be a more common phenomenon in the viable human germline than previously appreciated. For genome annotation, we investigated both LoF and gain-of-function (GoF) mutations. Absent molecular characterization of all variants, we adhered to the interpretation of previous exome-sequencing studies that classify a LoF mutation as any variant that disrupts the protein coding sequence. While haploinsufficiency of RNA cannot be confirmed without molecular evaluation, we have demonstrated in our previous BCA sequencing and 16p11.2 transcriptome sequencing studies that dosage compensation of a gene in which a single copy is disrupted is rare. 5, 30 We found an average of 25 LoF mutations per proband from all SVs in this study that meet this definition. For the purposes of this study and without access to material for molecular confirmation, we nominally defined GoF in this study as a copy gain of the entire gene, recognizing that an increase in mRNA may not correspond to a molecular gain of function; we observed this 17 times per proband. Importantly, the vast majority of observed LoF mutation (80%) would be cryptic to conventional CMA. In these analyses, we used 100 kb as a conservative estimate of CMA resolution, although many clinical CMA studies have lower resolution on the genomic backbone (e.g., it is approximately 240 kb on the SignatureChip Oligo Solution array) and higher resolution in targeted regions of known genomic disorders. 31 On average, the SVs detected result in 3.8 Mb of rearranged DNA per person (0.1% of haploid genome). A limitation of WGS as compared to CMA is the ability to detect CNVs in repetitive or misassembled genomic regions, such as segmental duplications or microsatellites. Given that several common genomic disorders are a consequence of segmental-duplication-mediated nonhomologous allelic recombination (NAHR) (e.g., 16p11.2 deletion/duplication, 22q11.2 deletion syndrome 32 ), we performed a complementary focal insert-depth analysis to survey genomic imbalance in these regions. Notably, BCAs localized to highly repetitive regions remain undetectable by this and all short-read sequencing methods. We modified a pre-existing WGS read-depth algorithm (cn.MOPS 33 ) to accommodate insert coverage rather than read depth. This modified method modeled normalized insert depth alterations simultaneously across all samples in 1, 3, 10, and 30 kb bins. We applied this insert-depth calling approach to 88 genomic regions corresponding to established genomic disorders already being investigated in prenatal diagnostic testing 22 and uncovered a 15q13.3 microduplication flanked by segmental duplicationsthus intractable to paired-end clustering alone-and previously identified as a duplication syndrome (Figure 1 ). 34 We confirmed this variant through microarray analysis of the 34, 36 and is not fully penetrant in the population. 36, 37 We found that a significant subset of the duplications observed involve insertion of a copy at a distant site, rather than being tandem duplications (9.9% above our high-confidence threshold in this cohort). One striking example involves two independent duplications on the same chromosome in a 19-year-old with ASD and ID, detectable by CMA, on 15q25 (360.3 kb) and 15q26 (169 kb) that flank a 5.25 Mb inversion, disrupting AKAP13 (MIM 604686) and IQGAP1 (MIM 603379) (Figure 2 ). We investigated duplication signatures at 15q25 and 15q26 in array CNV data from the Database of Genomic Variation 38 (DGV) and an internal CNV database of 33,573 independent cases sourced from clinical diagnostic laboratories and 13,989 controls from GWAS microarrays. 5 We detected 7 individuals with a similar duplication signature as our subject, suggesting that these subjects may harbor the same cryptic inversion. Interpretation of rare, private mutation remains a significant challenge in human genetic research and clinical diagnostics. To annotate detected genic disruptions in the absence of molecular characterization, we performed two stages of interpretation. In the first, we used the criteria established by Wapner et al. 22 for clinically significant SVs in prenatal diagnosis. This analysis required an SV to meet at least one of the following criteria to be considered pathogenic: (1) SV within or overlapping a targeted region from an established genomic disorder, (2) SV of 1 Mb or greater size not inherited from an unaffected parent, or (3) SV that disrupts a gene implicated in an autosomal-dominant Mendelian or X-linked disorder. Notably, these analyses encompass many of the criteria described for CMA testing of ASD or ID. Based upon these criteria, we found one likely pathogenic SV (the 15q13.3 duplication described above). We did not interpret the 5.3 Mb inversion flanked by ''paired'' duplications as pathogenic as it was inherited from an unaffected mother, and its molecular significance therefore warrants further investigation. The second stage of interpretation investigated only LoF variants with disruptions of at least one coding exon in a gene previously associated with NPDs and required a nominally significant CNV burden from cases with neurodevelopmental disorders obtained from clinical diagnostic laboratories compared to controls (total n ¼ 47,562). This convergent genomic approach was previously described in detail (see Talkowski et al.) . 5 We PCR-validated all putatively significant SVs in probands and available parental DNA; as above, we required any LoF variant passing these criteria to not be inherited from an unaffected parent. Considering these criteria, we found two additional private SVs to be potential NPD risk factors based upon disruption of a gene previously associated with NPDs and analyses that revealed a nominally significant increased CNV burden ( 43 Another variant detected lies in the promoter region of RBFOX1 (MIM 605104), which encodes a neuron-specific splicing factor involved with neuronal excitation 44 and has been implicated in a range of NPDs including intellectual disability, 45 ASD, 46, 47 and ADHD. 48 This 58 kb deletion was present in all affected members of our four-member family and thus appeared to segregate with NPDs. However, when we scrutinized available convergent genomic data for RBFOX1 from our clinical diagnostic CNV cohort, we found no evidence that dosage alterations of this locus represent an NPD risk factor (p % 0.995). Similar results have been previously observed in control cohorts. 49 Of these pathogenic or notable variants detected in our SV screen, four of the six SVs (66.7%) would be cryptic to CMA. There are limitations to interpretation of these findings. The sample size for this proof-of-concept study is small. Much larger cohorts are required to robustly establish estimates of cryptic SVs and clinical diagnostic yield from such populations. The jumping library method, as with all short-read sequencing approaches, is limited to detection of the portion of the human genome that can be uniquely aligned by short reads; SVs in highly repetitive regions are largely intractable to these methods and are not accounted for in this study. Further, our particular approach applied stringent filtering of SV clusters based on thresholds derived from validated variants in our training set. These data suggest that the method performed well in reducing false-positive SVs, but this was probably at a cost of increased false-negative results. Future studies in much larger samples and access to very deep WGS using longread technologies will greatly improve upon these initial estimates of cryptic SVs.
Taken together, these data provide insight into the landscape of cryptic SVs in clinically referred youth with severe NPDs, including youth with purely psychiatric conditions and youth with developmental disorders who have not previously been referred for genetic testing. We find that balanced and cryptic SVs represent an important and yet uncharacterized component of the genetic architecture of NPDs and warrant exploration in standard evaluation of severe psychiatric presentations in clinically referred youth. Moreover, our analyses establish that innovative sequencing approaches are capable of detecting pathogenic SVs that are currently detectable by CMA, as well as those that are cryptic to conventional technologies yet represent an important fraction of LoF mutation in a given genome. These data suggest that cost-effective WGS may represent a higher-resolution alternative testing modality to CMA or karyotyping for genome-wide SV assessment in clinical practice.
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